Torrent Pharmaceuticals completed the acquisition of Regestrone and Pregachieve brands in India from Swiss drug major Novartis AG. The flagship company of the Ahmedabad-based Rs 18,300 crore Torrent group had been in talks with Novartis to acquire to buy certain generic drugs from Swiss pharma major for quite some time.
The two brands widely prescribed by gynaecologists for the management of abnormal uterine bleeding, post- menopausal symptoms and infertility will now be under the Torrent portfolio.
Women's healthcare is an important therapy area for Torrent, which it intends to focus in the future. Regestrone and Pregachieve will further fortify the hormone segment. The use of hormones amongst the gynaecologists is on an increase because of lifestyle changes.
Last month, Torrent had announced inking of pacts with Novartis AG to acquire the two brands. It, however, did not disclose financial details.
Torrent Pharma has annual revenues of more than Rs 6,600 crore.
